A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bendamustine (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 24 Sep 2012 New trial record